Production (Stage)
Dianthus Therapeutics, Inc.
DNTH
$18.31
-$0.98-5.08%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 102.36% | 120.63% | 51.41% | 8.57% | -46.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 102.36% | 120.63% | 51.41% | 8.57% | -46.52% |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 102.36% | 120.63% | 51.41% | 8.57% | -46.52% |
| SG&A Expenses | 24.22% | 37.64% | 46.47% | 176.15% | 163.58% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.98% | 111.96% | 78.49% | 72.71% | 59.88% |
| Operating Income | -100.90% | -111.45% | -80.58% | -79.04% | -79.62% |
| Income Before Tax | -100.61% | -95.08% | -55.64% | -56.89% | -63.65% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -100.61% | -95.08% | -55.64% | -56.89% | -63.65% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -100.61% | -95.08% | -55.64% | -56.89% | -63.65% |
| EBIT | -100.90% | -111.45% | -80.58% | -79.04% | -79.62% |
| EBITDA | -100.99% | -111.55% | -80.61% | -79.05% | -79.62% |
| EPS Basic | 83.75% | 89.75% | 93.10% | 86.58% | 40.79% |
| Normalized Basic EPS | 83.45% | 89.65% | 93.02% | 86.54% | 40.72% |
| EPS Diluted | 83.75% | 89.75% | 93.10% | 86.58% | 40.79% |
| Normalized Diluted EPS | 83.45% | 89.65% | 93.02% | 86.54% | 40.72% |
| Average Basic Shares Outstanding | 207.72% | 530.86% | 1,568.15% | 2,147.23% | 582.49% |
| Average Diluted Shares Outstanding | 207.72% | 530.86% | 1,568.15% | 2,147.23% | 582.49% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |